PE20050197A1 - Anticuerpos de virus anti-dengue, composiciones, metodos y usos - Google Patents
Anticuerpos de virus anti-dengue, composiciones, metodos y usosInfo
- Publication number
- PE20050197A1 PE20050197A1 PE2004000111A PE2004000111A PE20050197A1 PE 20050197 A1 PE20050197 A1 PE 20050197A1 PE 2004000111 A PE2004000111 A PE 2004000111A PE 2004000111 A PE2004000111 A PE 2004000111A PE 20050197 A1 PE20050197 A1 PE 20050197A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- nucleic acid
- dengue virus
- refers
- dengue
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title abstract 4
- 206010012310 Dengue fever Diseases 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title abstract 4
- 208000025729 dengue disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 abstract 1
- 241000725619 Dengue virus Species 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO DEL VIRUS ANTI-DENGUE DE MAMIFERO AISLADO, QUE COMPRENDE POR LO MENOS UNA REGION VARIABLE COMPRENDIENDO LA SECUENCIA DE AMINOACIDO ESTABLECIDA EN SEC ID NOS: 3 O 4, EN DONDE DICHO ANTICUERPO UNE LA PROTEINA NS-1 DEL VIRUS DEL DENGUE. TAMBIEN SE REFIERE A MOLECULAS DE ACIDO NUCLEICO AISLADAS QUE SON COMPLEMENTARIAS O HIBRIDIZAN UN POLINUCLEOTIDO QUE CODIFICA ANTICUERPOS DE VIRUS ANTI-DENGUE ESPECIFICOS; VECTORES RECOMBINANTES QUE COMPRENDEN LAS MOLECULAS DE ACIDO NUCLEICO; UNA CELULA HUESPED PROCARIOTICA O EUCARIOTICA QUE COMPRENDE EL ACIDO NUCLEICO Y QUE ES SELECCIONADA DE CELULAS COS1, COS-7, HEK293, BHK1, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, DE MIELOMA O LINFOMA, O CUALQUIER CELULA DERIVADA; UN METODO PARA PRODUCIR DICHO ANTICUERPO QUE COMPRENDE TRADUCIR EL ACIDO NUCLEICO BAJO CONDICIONES IN VITRO, IN VIVO O IN SITU, DE MANERA QUE EL ANTICUERPO SEA EXPRESADO EN CANTIDADES DETECTABLES O RECUPERABLES. TAMBIEN SE REFIERE A UNA COMPOSICION Y DISPOSITIVO MEDICO QUE COMPRENDE AL MENOS DICHO ANTICUERPO Y OPCIONALMENTE JUNTO CON OTROS COMPUESTOS COMO UN ANTAGONISTA DE REPLICACION DEL VIRUS ANTIDENGUE, UN ANTIINFLAMATORIO NO ESTEROIDEO, UN ANALGESICO, ENTRE OTROS. Y A UN METODO PARA EL DIAGNOSTICO O TRATAMIENTO DE UNA CONDICION RELACIONADA CON EL VIRUS DEL DENGUE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44392403P | 2003-01-31 | 2003-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050197A1 true PE20050197A1 (es) | 2005-05-16 |
Family
ID=32825393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000111A PE20050197A1 (es) | 2003-01-31 | 2004-01-29 | Anticuerpos de virus anti-dengue, composiciones, metodos y usos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7473424B2 (es) |
| EP (1) | EP1592712A2 (es) |
| JP (1) | JP2007524350A (es) |
| AR (1) | AR042968A1 (es) |
| PE (1) | PE20050197A1 (es) |
| TW (1) | TW200508246A (es) |
| WO (1) | WO2004067567A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2894300A1 (en) * | 2003-12-08 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize dengue virus |
| JP4892548B2 (ja) * | 2005-05-02 | 2012-03-07 | アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル （アンセルム） | Ｈｉｖに対して中和活性を有する抗体又はその断片 |
| BRPI0816916A2 (pt) * | 2007-09-07 | 2014-09-30 | Mevlabs Inc | Formulações e dispositivos para liberação de compostos a artrópodes e microorganismos no interior dos mesmos. |
| WO2010043977A2 (en) * | 2008-10-13 | 2010-04-22 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| AU2013202434B2 (en) * | 2008-10-13 | 2016-01-28 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| US20130189275A1 (en) * | 2010-06-03 | 2013-07-25 | University Of Rochester | Compositions and methods for inhibition of or treatment of dengue virus infection |
| US8920804B2 (en) | 2011-12-22 | 2014-12-30 | Inbios International, Inc. | Methods and materials for the detection of dengue virus infection |
| KR102356951B1 (ko) | 2014-02-11 | 2022-01-27 | 비스테라, 인크. | 뎅기열 바이러스에 대한 항체 분자 및 그의 용도 |
| TWI511977B (zh) * | 2014-02-27 | 2015-12-11 | Univ Nat Cheng Kung | 抗登革熱病毒非結構性蛋白１之單株抗體及其用途 |
| WO2017011495A1 (en) * | 2015-07-14 | 2017-01-19 | Vanderbilt University | Engineered antibodies against dengue virus |
| KR101763745B1 (ko) | 2016-01-08 | 2017-08-01 | 전북대학교산학협력단 | 뎅기 바이러스 4가지 혈청형의 외막 도메인 ⅲ에 대한 단일클론 항체 및 이의 용도 |
| TWI763660B (zh) | 2016-03-25 | 2022-05-11 | 美商威特拉公司 | 登革病毒的抗體分子之配方設計 |
| KR102269663B1 (ko) * | 2018-04-27 | 2021-06-28 | 주식회사 레모넥스 | 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물 |
| KR101995774B1 (ko) * | 2018-05-08 | 2019-07-03 | 한국세라믹기술원 | 뎅기열 바이러스에 특이적으로 결합하는 피브로넥틴 edb 단백질 스캐폴드 |
| US20210188948A1 (en) * | 2018-08-07 | 2021-06-24 | Chan Zuckerberg Biohub, Inc. | Antibodies against dengue virus and related methods |
| CN115785262B (zh) * | 2021-09-10 | 2023-09-22 | 东莞市朋志生物科技有限公司 | 一种抗登革ns1蛋白的抗体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ501990A (en) * | 1997-07-08 | 2002-09-27 | Viventia Biotech Inc | Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody |
| AU754386B2 (en) * | 1997-09-23 | 2002-11-14 | Bavarian Nordic A/S | Dengue virus antigens and treatment of dengue fever |
| FR2794865B1 (fr) * | 1999-06-09 | 2003-04-18 | Pasteur Institut | Methode de detection precoce des flavivirus et ses applications |
| FR2794864A1 (fr) * | 1999-06-09 | 2000-12-15 | Pasteur Institut | Methode de detection precoce des flavivirus et ses applications |
| JP2006503547A (ja) * | 2002-02-11 | 2006-02-02 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 生物兵器防衛のための免疫療法 |
-
2004
- 2004-01-12 US US10/756,125 patent/US7473424B2/en not_active Expired - Fee Related
- 2004-01-29 PE PE2004000111A patent/PE20050197A1/es not_active Application Discontinuation
- 2004-01-30 EP EP04706641A patent/EP1592712A2/en not_active Withdrawn
- 2004-01-30 WO PCT/EP2004/000896 patent/WO2004067567A2/en active Application Filing
- 2004-01-30 JP JP2006501690A patent/JP2007524350A/ja active Pending
- 2004-01-30 TW TW093102206A patent/TW200508246A/zh unknown
- 2004-12-29 AR ARP040100270A patent/AR042968A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US7473424B2 (en) | 2009-01-06 |
| US20040209244A1 (en) | 2004-10-21 |
| AR042968A1 (es) | 2005-07-13 |
| EP1592712A2 (en) | 2005-11-09 |
| TW200508246A (en) | 2005-03-01 |
| JP2007524350A (ja) | 2007-08-30 |
| WO2004067567A2 (en) | 2004-08-12 |
| WO2004067567A3 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050197A1 (es) | Anticuerpos de virus anti-dengue, composiciones, metodos y usos | |
| DK1666052T3 (da) | Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer | |
| AR064642A1 (es) | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi | |
| Bulaj et al. | δ-Conotoxin structure/function through a cladistic analysis | |
| BRPI0508670A (pt) | proteìnas de buganina modificada, citotoxinas e métodos e usos delas | |
| GT201000148A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| BR0315666A (pt) | Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos | |
| IL129299A0 (en) | Monoclonal antibodies antigens and diagnosis of malignant diseases | |
| AR033978A1 (es) | Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas | |
| AR046833A1 (es) | Anticuerpos anti-interleuquina-10 | |
| BR9608558A (pt) | Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução | |
| ME00356B (me) | Novi peptidi koji se vezuju za receptor eritropoietina | |
| ECSP099379A (es) | Anticuerpos anti-factor d humanizados | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| EA200000298A1 (ru) | Агонисты простагландинов и их применение для лечения заболеваний костей | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| EA200600055A1 (ru) | Агонисты рецептора меланокортина 4 (мк4 ) и их применение | |
| PE20080187A1 (es) | Agonistas receptores de eritropoietina | |
| DE602006012995D1 (de) | Brustkrebsdiagnoseverfahren | |
| DE602004016499D1 (de) | Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung | |
| BRPI0515893B8 (pt) | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica. | |
| ATE545708T1 (de) | Krebsantigen mage-a9 und verwendungen davon | |
| PE20061441A1 (es) | Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia | |
| ATE538811T1 (de) | Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44 | |
| BRPI0409736A (pt) | anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |